Exelixis Ryvu enter license agreement to develop novel STING agonist based targeted cancer therapies
By, Admin1 min read
Share
Exelixis, Inc. and Ryvu Therapeutics S.A. (Ryvu) announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
